Haghighi Fatemeh, Yesylevskyy Semen, Davani Siamak, Ramseyer Christophe
Laboratoire Chrono Environnement UMR CNRS 6249, Université de Bourgogne Franche-Comté, 16 route de Gray, CEDEX, 25030 Besançon, France.
Unité de Recherche EA 3920, Université de Bourgogne Franche-Comté, 19 rue Ambroise Paré, CEDEX, 25000 Besançon, France.
Pharmaceutics. 2021 Apr 9;13(4):524. doi: 10.3390/pharmaceutics13040524.
The binding of natural ligands and synthetic drugs to the P2Y12 receptor is of great interest because of its crucial role in platelets activation and the therapy of arterial thrombosis. Up to now, all computational studies of P2Y12 concentrated on the available crystal structures, while the role of intrinsic protein dynamics and the membrane environment in the functioning of P2Y12 was not clear. In this work, we performed all-atom molecular dynamics simulations of the full-length P2Y receptor in three different membrane environments and in two possible conformations derived from available crystal structures. The binding of ticagrelor, its two major metabolites, adenosine diphosphate (ADP) and 2-Methylthioadenosine diphosphate (2MeS-ADP) as agonist, and ethyl 6-[4-(benzylsulfonylcarbamoyl)piperidin-1-yl]-5-cyano-2-methylpyridine-3-carboxylate (AZD1283)as antagonist were assessed systematically by means of ensemble docking. It is shown that the binding of all ligands becomes systematically stronger with the increase of the membrane rigidity. Binding of all ligands to the agonist-bound-like conformations is systematically stronger in comparison to antagonist-bound-likes ones. This is dramatically opposite to the results obtained for static crystal structures. Our results show that accounting for internal protein dynamics, strongly modulated by its lipid environment, is crucial for correct assessment of the ligand binding to P2Y12.
天然配体和合成药物与P2Y12受体的结合备受关注,因为它在血小板活化和动脉血栓治疗中起着关键作用。到目前为止,所有关于P2Y12的计算研究都集中在现有的晶体结构上,而内在蛋白质动力学和膜环境在P2Y12功能中的作用尚不清楚。在这项工作中,我们在三种不同的膜环境以及从现有晶体结构衍生出的两种可能构象下,对全长P2Y受体进行了全原子分子动力学模拟。通过系综对接系统地评估了替格瑞洛及其两种主要代谢产物二磷酸腺苷(ADP)和2-甲硫基二磷酸腺苷(2MeS-ADP)作为激动剂,以及6-[4-(苄基磺酰基氨基甲酰基)哌啶-1-基]-5-氰基-2-甲基吡啶-3-羧酸乙酯(AZD1283)作为拮抗剂的结合情况。结果表明,随着膜刚性的增加,所有配体的结合都系统性地增强。与拮抗剂结合样构象相比,所有配体与激动剂结合样构象的结合系统性地更强。这与静态晶体结构得到的结果截然不同。我们的结果表明,考虑到受其脂质环境强烈调节的内部蛋白质动力学,对于正确评估配体与P2Y12的结合至关重要。